Form 8-K Filing Summary

Ginkgo Bioworks Holdings, Inc. announced a significant leadership transition. Dr. Reshma Shetty, President and COO, will transition her COO duties to Jennifer Wipf and CEO Dr. Jason Kelly, effective January 1, 2026. Dr. Shetty will remain President and on the Board, focusing on expanding the company's autonomous lab for cell engineering services. Dr. Kelly will assume principal operating officer functions. Jennifer Wipf, formerly Chief Commercial Officer, will take on operational responsibilities including commercial operations, procurement, and people operations, reporting to Dr. Kelly. Ms. Wipf brings extensive experience from Merck & Co. in vaccine development and plant management.